Selected article for: "lung injury and viral load"
Author: Muslim, Shahnawaz; Nasrin, Nasrin; Alotaibi, Faisal Obaid; Prasad, Geeta; Singh, Shambhu Kumar; Alam, Izhar; Mustafa, Gulam
Title: Treatment Options Available for COVID-19 and an Analysis on Possible Role of Combination of rhACE2, Angiotensin (1-7) and Angiotensin (1-9) as Effective Therapeutic Measure
  • Cord-id: 9ta15h41
  • Document date: 2020_8_22
    • ID: 9ta15h41
    Snippet: Corona virus disease (COVID-19), caused by SARS-CoV-2, is rapidly spreading all around the world and is posing a threat to mankind. Since SARS-CoV-2 is a novel virus, little is known about it and no effective drug is available for its treatment. While many drugs are being evaluated, an effective therapeutic measure is still lacking. SARS-CoV-2 like SARS-CoV binds with angiotensin-converting enzyme 2 (ACE2) present on human cells. SARS-CoV has been found to downregulate ACE2 and SARS- CoV-2 infec
    Document: Corona virus disease (COVID-19), caused by SARS-CoV-2, is rapidly spreading all around the world and is posing a threat to mankind. Since SARS-CoV-2 is a novel virus, little is known about it and no effective drug is available for its treatment. While many drugs are being evaluated, an effective therapeutic measure is still lacking. SARS-CoV-2 like SARS-CoV binds with angiotensin-converting enzyme 2 (ACE2) present on human cells. SARS-CoV has been found to downregulate ACE2 and SARS- CoV-2 infection has been found to be associated with increased level of Angiotensin II. Based on these facts, we presume that SARS-CoV-2 like SARS-CoV downregulates ACE2, and in absence/reduced activity of ACE2, level of angiotensin (1-7) and angiotensin (1-9) is decreased while that of angiotensin II is increased and increased level of angiotensin II has been found to correlate with lung injury and viral load. We presume that restoration of normal functioning of renin-angiotensin system with recombinant human angiotensin-converting enzyme 2 (rhACE2), angiotensin (1-7) and angiotensin (1-9) may be an effective therapeutic measure but studies will be required to test this hypothesis and explore its possible role in treatment of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • lmwh weight heparin and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • load reduction and lopinavir ritonavir: 1, 2, 3, 4
    • load reduction and lung imaging: 1
    • lopinavir ritonavir and low molecular lmwh weight heparin: 1, 2, 3
    • lopinavir ritonavir and low potency: 1
    • lopinavir ritonavir and lung ct finding: 1
    • lopinavir ritonavir and lung imaging: 1, 2, 3, 4
    • lopinavir ritonavir and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • lopinavir ritonavir and macrolide antibiotic: 1, 2
    • lopinavir ritonavir combination and lung injury: 1, 2
    • lopinavir ritonavir combination and macrolide antibiotic: 1
    • lopinavir ritonavir therapy and lung injury: 1
    • lopinavir ritonavir therapy and macrolide antibiotic: 1
    • lopinavir treatment ritonavir and lung ct finding: 1
    • lopinavir treatment ritonavir and lung imaging: 1, 2
    • lopinavir treatment ritonavir and lung injury: 1, 2, 3
    • lopinavir treatment ritonavir and macrolide antibiotic: 1
    • low molecular lmwh weight heparin and lung injury: 1, 2
    • low potency and lung injury: 1